This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Human Chorionic Gonadotropin (hCG) Test: A Novel Method to Evaluate the Ovarian Reserve

This study has been completed.
Information provided by:
Hadassah Medical Organization Identifier:
First received: March 17, 2008
Last updated: June 22, 2011
Last verified: June 2011

In an era of delayed fertility plans, there is an increasing need for a reliable method to predict ovarian reserve and responsiveness. The current tests include serum FSH, Inhibin B, Mullerian inhibiting factor (MIF) and ultrasonographic measures such as ovarian volume and number of antral follicles are non-specific and with questionable reliability. The biochemical tests represent the function of production of androgens, as a predictor of ovarian reserve, has not been tested yet.

Working hypothesis and aims: testing the prognostic capability of hCG stimulating test of theca cells for estimating the ovarian reserve, and by that to calculate better the chance for IVF cycle success

Condition Intervention
Infertility Drug: s.c. human chorionic gonadotropin (Pregnyl)

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: hCG Stimulating Test of the Thecal Cells to Evaluate the Ovarian Reserve

Resource links provided by NLM:

Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:
  • androgens levels after stimulation in relation to the ovarian reserve [ Time Frame: 2 weeks ]

Estimated Enrollment: 60
Study Start Date: June 2008
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: s.c. human chorionic gonadotropin (Pregnyl)
    S.C. Pregnyl 10000 IU once
Detailed Description:
20 women >40 years old and 20 women <35 years old, attended to our IVF unit were included in the study. Another 20 other young women (<35 years) with poor response in previous IVF cycles will be participate. All participants received a single hCG 10000 IU injection on cycle day 2-4. Hormone levels of LH, FSH, E2, P, Testosterone, Androstendione and 17-OHP were taken prior to the injection and on days 1, 3 and 7 afterwards. hCG induced hormone levels will be compared with IVF results

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All women on IVF cycle

Exclusion Criteria:

  • Any allergy to injection of human chorionic gonadotropin before
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00646568

Hadassah Medical center
Jerusalem, Israel, 12000
Sponsors and Collaborators
Hadassah Medical Organization
Principal Investigator: Assaf Ben-Meir, MD Hadassah Medical Organization
  More Information

Responsible Party: Arik Tzukert, Hadassah Medical Center Identifier: NCT00646568     History of Changes
Other Study ID Numbers: hcgstimtest-HMO-CTIL
Study First Received: March 17, 2008
Last Updated: June 22, 2011

Keywords provided by Hadassah Medical Organization:
ovarian reserve
thecal cells
Fertility Agents, Female

Additional relevant MeSH terms:
Genital Diseases, Male
Genital Diseases, Female
Chorionic Gonadotropin
Reproductive Control Agents
Physiological Effects of Drugs processed this record on September 20, 2017